Neurosearch A/s

Meiji Seika Kaisha, Ltd.

Nuevolution A/s

Poseidon Pharmaceuticals A/s

N.v. Organon

Saniona A/s

Lene Teuber

Palle Christophersen

Dan Peters

Philip K Ahring

Janus Schreiber Larsen

Bo Skaaning Jensen

Naheed Mirza

Elsebet Østergaard Nielsen

Frank Watjen

Ulrik Svane Sørensen

Tina Holm Johansen

Dorte Strobaek

Alex Haahr Gouliaev

Dorte Strøbæk

Birgitte Langer Eriksen

William Dalby Brown

Sanne Schrøder Glad

Karin Sandager Nielsen

Ian Sarvary

Luigi Piero Stasi

David Tristram Brown

Oskar Axelsson

Toshiro Sasaki

Yoshimasa Fukuda

Charlotte Hougaard

Joachim Demnitz

Tino Dyhring Jørgensen

Bjarne H Dahl

Soren Peter Olesen

S&oslash;ren Peter Olesen

Niels Grøn Nørager

Frank W&auml;tjen

Osamu Ushiroda

Sanne Schroder Glad

Dorte Str&oslash;b&aelig;k

Frank Abildgaard Slok

Niels Gron Norager

Andrew Cooke

Kim Birkebaek Jensen

Susan Elizabeth Napier

Frank Wätjen

Kim Birkebæk Jensen

Niall Morton Hamilton

Visnja Poljak

Tine Titilola Akinleminu Kronborg

Søren Peter Olesen

Mikkel Vestergaard

Frank W Atjen

Morag Ann MacCall Easson

Jurgen Beyer

Dorte Strøbaek

Jimmi Gerner Seitzberg

Dorte Str&oslash;baek

Tine Titilola Akinlemnu Kronborg

Gitte Friberg

Janus S Larsen

Niels GRØN NØRAGER

Kim BIRKEBÆK Jensen

Elsebet ØStergaard Nielsen

Frank Abildgaard Slök

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

Disclosed are compounds towards bromodomains, pharmaceutical compositions containing the compounds and use of the compounds in therapy. 

Compounds active towards bromodomains

Disclosed are compounds of Formula I, which are active toward nuclear receptors such as nuclear retinoic acid receptor-related orphan receptors (RORs), pharmaceutical compositions containing the compounds of Formula I, and methods of treating inflammatory, metabolic, oncologic and autoimmune diseases or disorders using the of the compounds Formula I in therapy. 

Benzimidazole derivatives, pharmaceutical compositions containing them, and methods of treatment therewith involving modulation of the GABAreceptor complex. The compounds have the formula I: wherein the variables are as described in the specification. The compounds are useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

[object Object]

This invention relates to novel potassium channel modulating agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular respiratory diseases, epilepsy, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, schizophrenia, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labour, baldness, cancer, immune suppression or pain.

Potassium channel modulating agents and their medical use

Potassium channel modulating agents of Formula Ia or Ib and enantiomers and mixtures enantiomers and N-oxides thereof, and pharmaceutically acceptable salts thereof, and their use in the preparation of pharmaceutical compositions. Also, pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, e.g., respiratory diseases, epilepsy, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, schizophrenia, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, immune suppression, or pain.

Indazolyl derivatives useful as potassium channel modulating agents

This invention relates to novel guanidine derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

Guanidine derivatives and their medical use

This invention relates to novel 2-amino-pyridine derivative useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

2-aminio-pyridine derivatives and their use as potassium channel modulators

This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

Imidazole derivatives for the treatment of anxiety and related diseases

This invention relates to novel 2-(phenylamino)benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels

This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are of the general formula (I) and include any of its stereoisomers, any mixture of its stereoisomers, and pharmaceutically acceptable salts thereof. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases. 

Growing community of inventors

Værløse, Denmark

Lene Teuber